These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9331125)

  • 21. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer.
    Hainsworth JD; Greco FA
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):60-6. PubMed ID: 10190785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of escalating doses of paclitaxel (Taxol) with fixed doses of ifosfamide, carboplatin, and etoposide.
    Boros L; Garrow GC; Asbury RF; Chang AY
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):28-31. PubMed ID: 7610396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New treatment agents for advanced small cell and non-small cell lung cancer.
    Bunn PA; Kelly K
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):53-63. PubMed ID: 7597434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
    Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
    Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
    J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel via 1-hour infusion: clinical experience.
    Greco FA; Hainsworth JD
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):91-3. PubMed ID: 9007131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
    Fabi A; Barduagni M; Ferraresi V; Cortesi E; Gamucci T; De Marinis F; Saltarelli R; Gabriele A; Pellicciotta M; Ceribelli A; De Marco S; Facciolo F; Cognetti F
    J Exp Clin Cancer Res; 2004 Mar; 23(1):25-32. PubMed ID: 15149147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
    Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
    Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
    Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ifosfamide-based chemotherapy for non-small cell lung cancer: phase I/II studies at the University of Chicago.
    Vokes EE; Hoffman PC; Masters GA; Golomb HM; Drinkard LC; Krauss SA
    Semin Oncol; 1996 Jun; 23(3 Suppl 7):15-8. PubMed ID: 8711496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management (chemotherapy/best supportive care) of advanced-stage non-small cell lung cancer.
    Carney DN
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):58-62. PubMed ID: 7644930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.
    Markman M
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):88-9. PubMed ID: 7597438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group.
    Postmus PE; Giaccone G; Debruyne C; Sahmoud T; Splinter TA; van Zandwijk N
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):10-3. PubMed ID: 8941404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy in the management of patients with inoperable non-small cell lung cancer.
    Carney DN
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):71-5. PubMed ID: 9007127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative paclitaxel plus carboplatin for patients with intermediate-risk non-small cell lung cancer.
    Ruckdeschel JC
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):62-7. PubMed ID: 9007125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ifosfamide in non-small cell lung cancer.
    Johnson DH
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):7-10. PubMed ID: 8677453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer.
    Novello S; Le Chevalier T
    Semin Oncol; 2001 Aug; 28(4 Suppl 14):3-9. PubMed ID: 11605176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ifosfamide in non-small-cell lung cancer.
    Rosell R; Martin C; Balaña C
    Ann Oncol; 1999; 10 Suppl 5():S25-8. PubMed ID: 10582135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.